Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17580791 | 0.92 | CHRNB2 (0.46) | HTR6BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL17580927 | 0.92 | HTR6 (0.46) | HTR6CHRNB2CHRNA4CHRNA7HTR2A | |
| SCHEMBL17580665 | 0.89 | PIK3CA (0.42) | HTR6NAMPT | |
| SCHEMBL17580778 | 0.87 | PIM1 (0.49) | HTR6NAMPT | |
| SCHEMBL17580661 | 0.86 | HTR6 (0.40) | HTR6BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL17580612 | 0.85 | HTR6 (0.44) | HTR6BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL17580617 | 0.85 | HTR6 (0.42) | HTR6HTR2A | |
| SCHEMBL17580675 | 0.85 | HTR6 (0.44) | HTR6HTR2AHTR7HTR1ADRD2 | |
| SCHEMBL17580798 | 0.83 | HTR6 (0.44) | HTR6HTR2AHTR7HTR1ADRD2 | |
| SCHEMBL3643424 | 0.83 | HTR6 (0.58) | HTR6BPTFCHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185555-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2016-03-16 | — | — | EP | claimed |